We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drug Review Amendments Meet With Mixed Success
Drug Review Amendments Meet With Mixed Success
May 24, 2006
A controversial amendment to a House appropriations bill giving the FDA new authority to require postmarket studies was stripped from the legislation in May, while another divisive provision eliminating conflict-of-interest waivers for advisory boards lives on.